You are here
Secretech, Inc.
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
NEW STRATEGIES FOR IMMUNIZATION AGAINST INFLUENZA VIRUS
Amount: $438,684.00THE PURPOSE OF THE PHASE I STUDY IS TO EXPLORE A NOVEL APPROACH FOR INFLUENZA VIRUS VACCINATION BY USING MICROENCAPSULATED ANTIGENS ADMINISTERED BY THE ORAL OR INTRANASAL ROUTE IN ORDER TO INDUCE A PR ...
SBIRPhase II1993Department of Health and Human Services -
Novel Adjuvant to Enhance Immunity Against PIV3
Amount: $50,000.00We will apply a novel adjuvant to the production of an effective, safe vaccine against PIV3. The proposed adjuvant is a proprietary formulation of microcrystalline cellulose, starch, and sugar. We wil ...
SBIRPhase I1993Department of Health and Human Services -
CTB as an Oral Adjuvant for Parainfluenza Vaccine
Amount: $48,156.00The long term objective is to develop a commercial trivalent glycoprotein subunit vaccine for parainfluenza viruses. Because of the high cost of preparing these glycoproteins, a means for achieving an ...
SBIRPhase I1993Department of Health and Human Services -
Microencapsulated Respiratory Syncytial Virus Vaccine
Amount: $50,000.00The long term objective is to develop a commercial subunit vaccine for human respiratory syncytial virus (RSV). Because of the high cost of preparing these glycoproteins, a means for achieving an enha ...
SBIRPhase I1993Department of Health and Human Services -
Mucosal Immunity Against Non-infectious SIV Particles
Amount: $49,999.00The long term objective is to induce a protective mucosal immune response to prevent HIV-1 infection. We will immunize orally with recombinant defective SIV-like particles entrapped in microcapsules o ...
SBIRPhase I1993Department of Health and Human Services -
Mucosal Vaccine for Sexually Transmitted Chlamydia
Amount: $50,000.00The long term objective is to develop a commercial vaccine for the prophylactic treatment of sexually transmitted Chlamydia trachomatis. Parenteral or oral delivery of free antigen does not protect ag ...
SBIRPhase I1993Department of Health and Human Services -
Microencapsulated Measles Virus Vaccine
Amount: $50,000.00The long term objective is to develop a commercial subunit vaccine against MV infection. Because of the high cost of preparing the surface antigens, a means for achieving an enhanced immune response i ...
SBIRPhase I1993Department of Health and Human Services -
VACCINE DELIVERY SYSTEM FOR LIVE ROTAVIRUS VACCINES
Amount: $290,133.00THE LONG-TERM OBJECTIVE OF THIS STUDY IS THE DEVELOPMENT OF AN EFFECTIVE DELIVERY SYSTEM FOR A LIVE HUMAN ROTAVIRUS VACCINE. TO AVOID THE INACTIVATION OF VIRUS BY GASTRIC ACID, DIFFERENT BUFFERS ARE B ...
SBIRPhase II1992Department of Health and Human Services -
HUMAN PARAINFLUENZA TYPE 2 VIRUS GLYCOPROTEIN GENES
Amount: $499,576.00IT IS PLANNED TO CONSTRUCT A CDNA LIBRARY OF HUMAN PARAINFLUENZA TYPE 2 VIRUS MRNA'S INTO A PLASMID VECTOR. THE LIBRARY WILL BE SCREENED BY COLONY HYBRIDIZATION. THE GENES ENCODING ENVELOPE GLYCOPROTE ...
SBIRPhase II1991Department of Health and Human Services -
NEW STRATEGIES FOR IMMUNIZATION AGAINST INFLUENZA VIRUS
Amount: $50,000.00N/A
SBIRPhase I1991Department of Health and Human Services